Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and optimal dosing of cefmetazole, flomoxef and ceftolozane-tazobactam for SSI prophylaxis after lower GI surgery
jRCTs061190025Completed
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cefmetazole, flomoxef and ceftolozane + tazobactam in surgical site infection (SSI) and Extended-spectrum beta-lactamase-producing Escherichia coli infection (3 arms). Primary endpoint: Pharmacokinetic parameters of cefmetazole, flomoxef and ceftolozane-tazobactam. Started Jan 2020; status: completed.
02
Drugs
cefmetazoleflomoxefceftolozane + tazobactam
03
Conditions
surgical site infection (SSI)Extended-spectrum beta-lactamase-producing Escherichia coli infection
Beyond the preview
Go deeper on jRCTs061190025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061190025.